Loading
Houston oncologist who led the trial that established belzutifan, the first drug for the tumours of von Hippel-Lindau disease, including kidney cancers, pancreatic tumours and haemangioblastomas.
Eric Jonasch is a genitourinary medical oncologist at MD Anderson Cancer Center and directs its von Hippel-Lindau clinical centre. He was first author of the 2021 New England Journal of Medicine report of the phase 2 trial in which the HIF-2α inhibitor belzutifan shrank renal cell carcinomas and also pancreatic lesions and central nervous system haemangioblastomas in patients with VHL disease, leading to the first approval of a drug for the syndrome.
| Title | Journal | Year |
|---|---|---|
| Belzutifan for renal cell carcinoma and other tumours in von Hippel-Lindau disease | New England Journal of Medicine | 2021 |
Shares MD Anderson Cancer Center and the tags targeted-therapy, trialist.
Shares the tags targeted-therapy, trialist.
Shares the tags targeted-therapy, trialist.
Shares the tags targeted-therapy, trialist.
Shares the tags targeted-therapy, trialist.
Shares the tags targeted-therapy, trialist.
Shares the tags targeted-therapy, trialist.
Shares the tags targeted-therapy, trialist.